Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Sep 07, 2025
Episode
313
Soundcloud
Share
In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. David Planchard discusses the data that we have all been waiting for: the FLAURA-2 overall survival. Dr. Alexander Drilon shares results from the ARROS-1 study, including efficacy results and safety data for zidesamtinib, a new ROS1 inhibitor that could change the landscape in the ROS1 space.
Guest
Stephen Liu
MD
Chief of Hematology and Oncology
Georgetown University
Alexander Drilon
MD
Memorial Sloan Kettering Cancer Center
David Planchard
MD, PhD
Thoracic Oncologist
University Paris Saclay
